Инструмент | Доходность к погашению % | Объём | Цена % | Купонная доходность % | Срок погашения | Задолженность | Номинал | Мин. деноминация | Эмитент |
---|---|---|---|---|---|---|---|---|---|
TTEVA.GJTeva Pharmaceutical Finance Co. LLC 0.25% 01-FEB-2026 | 8,75% | 9 K | 91,00% | 0,25% | 2026-02-01 | 22,88 M USD | 1 000,00 USD | 1 000,00 USD | Teva Pharmaceutical Finance Co. LLC |
XXS181372460TEVA PH.F.NL.II 18/25 | 7,62% | 0 | 99,56% | 4,50% | 2025-03-01 | 494,35 M EUR | 1 000,00 EUR | 100 000,00 EUR | Teva Pharmaceutical Finance Netherlands II BV |
TTFACTEVA P.FI.NL III 16/46 | 7,48% | 0 | 72,00% | 4,10% | 2046-10-01 | 2 B USD | 1 000,00 USD | 2 000,00 USD | Teva Pharmaceutical Finance Netherlands III BV |
TTEVA4608603Teva Pharmaceutical Finance Netherlands III BV 6.75% 01-MAR-2028 | 6,96% | 1 M | 99,25% | 6,75% | 2028-03-01 | 255 K USD | 1 000,00 USD | 200 000,00 USD | Teva Pharmaceutical Finance Netherlands III BV |
TTEVA5034099Teva Pharmaceutical Finance Netherlands III BV 7.125% 31-JAN-2025 | 6,67% | 2,51 M | 100,03% | 7,13% | 2025-01-31 | 425,26 M USD | 1 000,00 USD | 200 000,00 USD | Teva Pharmaceutical Finance Netherlands III BV |
TTEVA4914602Teva Pharmaceutical Finance Netherlands III BV 7.125% 31-JAN-2025 | 6,44% | 0 | 101,25% | 7,13% | 2025-01-31 | 1,25 M USD | 1 000,00 USD | 200 000,00 USD | Teva Pharmaceutical Finance Netherlands III BV |
UUS88163VAD1TEVA PHARM.FIN. 2036 | 6,15% | 0 | 100,01% | 6,15% | 2036-02-01 | 789,43 M USD | 1 000,00 USD | 2 000,00 USD | Teva Pharmaceutical Finance Co. LLC |
TTEVA5295245Teva Pharmaceutical Finance Netherlands III BV 5.125% 09-MAY-2029 | 6,09% | 2,42 M | 96,70% | 5,13% | 2029-05-09 | 1 B USD | 1 000,00 USD | 200 000,00 USD | Teva Pharmaceutical Finance Netherlands III BV |
TTEVA5295244Teva Pharmaceutical Finance Netherlands III BV 4.75% 09-MAY-2027 | 5,85% | 2,59 M | 97,75% | 4,75% | 2027-05-09 | 1 B USD | 1 000,00 USD | 200 000,00 USD | Teva Pharmaceutical Finance Netherlands III BV |
TTEVA4608604Teva Pharmaceutical Finance Netherlands III BV 6.75% 01-MAR-2028 | 5,78% | 2,95 M | 102,60% | 6,75% | 2028-03-01 | 1,25 B USD | 1 000,00 USD | 200 000,00 USD | Teva Pharmaceutical Finance Netherlands III BV |
TTFABTEVA P.FI.NL III 16/26 | 5,70% | 0 | 95,98% | 3,15% | 2026-10-01 | 3,38 B USD | 1 000,00 USD | 2 000,00 USD | Teva Pharmaceutical Finance Netherlands III BV |
TTEVA5549923Teva Pharmaceutical Finance Netherlands III BV 7.875% 15-SEP-2029 | 5,69% | 4,21 M | 108,08% | 7,88% | 2029-09-15 | 600 M USD | 1 000,00 USD | 200 000,00 USD | Teva Pharmaceutical Finance Netherlands III BV |
TTEVA5549924Teva Pharmaceutical Finance Netherlands III BV 8.125% 15-SEP-2031 | 5,58% | 4 M | 112,38% | 8,13% | 2031-09-15 | 500 M USD | 1 000,00 USD | 200 000,00 USD | Teva Pharmaceutical Finance Netherlands III BV |
XXS259280419TEV.P.F.N.II 23/31 | 3,92% | 0 | 120,98% | 7,88% | 2031-09-15 | 500 M EUR | 1 000,00 EUR | 100 000,00 EUR | Teva Pharmaceutical Finance Netherlands II BV |
XXS219821395TEVA PHARM FINANCE NL II 6% GTD SNR NTS 31/01/2025 EUR100000 | 3,88% | 0 | 100,14% | 6,00% | 2025-01-31 | 410,61 M EUR | 1 000,00 EUR | 100 000,00 EUR | Teva Pharmaceutical Finance Netherlands II BV |
XXS240660717TEV.P.F.N.II 21/30 | 3,82% | 0 | 102,48% | 4,38% | 2030-05-09 | 1,5 B EUR | 1 000,00 EUR | 100 000,00 EUR | Teva Pharmaceutical Finance Netherlands II BV |
XXS259280443TEV.P.F.N.II 23/29 | 3,75% | 0 | 114,45% | 7,38% | 2029-09-15 | 800 M EUR | 1 000,00 EUR | 100 000,00 EUR | Teva Pharmaceutical Finance Netherlands II BV |
XXS240660709TEV.P.F.N.II 21/27 | 3,66% | 0 | 100,20% | 3,75% | 2027-05-09 | 1,1 B EUR | 1 000,00 EUR | 100 000,00 EUR | Teva Pharmaceutical Finance Netherlands II BV |
XXS143974936TEVA PH.F.NL.II 16/28 | 3,61% | 0 | 93,41% | 1,63% | 2028-10-15 | 750 M EUR | 1 000,00 EUR | 100 000,00 EUR | Teva Pharmaceutical Finance Netherlands II BV |
XXS121104407TEVA PH.F.NL.II 15/27 | 3,50% | 0 | 96,65% | 1,88% | 2027-03-31 | 700 M EUR | 1 000,00 EUR | 100 000,00 EUR | Teva Pharmaceutical Finance Netherlands II BV |
CCH33382750TEVA PH.FI.NL IV 16-25 | 2,00% | 0 | 99,46% | 1,00% | 2025-07-28 | 350 M CHF | 5 000,00 CHF | 5 000,00 CHF | Teva Pharmaceutical Finance Netherlands IV BV |